January 24, 2018 / 10:07 PM / 3 months ago

BRIEF-Iovance Announces Preliminary Phase 2 Data For Til Treatment In Head And Neck And Cervical Cancers

Jan 24 (Reuters) - Iovance Biotherapeutics Inc:

* IOVANCE BIOTHERAPEUTICS ANNOUNCES PRELIMINARY PHASE 2 DATA FOR TIL TREATMENT IN HEAD AND NECK AND CERVICAL CANCERS

* 3 OF 8 PATIENTS TREATED WITH LN-145 HAD REDUCTION IN TUMOR SIZE OF AT LEAST 30 PCT & QUALIFIED AS PARTIAL RESPONSE

* 1 OF 2 EVALUABLE PATIENTS WITH RECURRENT, METASTATIC/PERSISTENT CERVICAL CARCINOMA TREATED WITH LN-145 EXPERIENCED CONFIRMED PARTIAL RESPONSE WILL CONTINUE TO ENROLL PATIENTS IN STUDY TO FULL SAMPLE SIZE OF 47 PER PROTOCOL

* ONE PATIENT TREATED WITH LN-145 HAD A CONFIRMED PR AND ONE HAD STABLE DISEASE AS PER PRELIMINARY DATA FROM C-145-04 STUDY

* REPORTED PRELIMINARY CLINICAL RESULTS FROM TWO ONGOING OPEN-LABEL PHASE 2 STUDIES IN HEAD AND NECK AND CERVICAL CANCERS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below